Effects of the oral, direct factor Xa inhibitor edoxaban on routine coagulation assays, lupus anticoagulant and anti-Xa assays
Sign Up to like & getrecommendations! Published in 2018 at "Scandinavian Journal of Clinical and Laboratory Investigation"
DOI: 10.1080/00365513.2018.1522664
Abstract: Abstract Edoxaban is an oral direct factor Xa inhibitor for prophylaxis and treatment of thromboembolic disorders. The effects on common coagulation assays are clinically valuable information and in certain clinical situations a quick assessment of… read more here.
Keywords: coagulation; anti assays; coagulation assays; oral direct ... See more keywords
Managing patients on direct factor Xa inhibitors with rapid thrombelastography.
Sign Up to like & getrecommendations! Published in 2021 at "Scandinavian journal of clinical and laboratory investigation"
DOI: 10.1080/00365513.2021.2003855
Abstract: The use of direct factor Xa inhibitors rivaroxaban and apixaban (XABANs) has rapidly increased; however, there is no validated test available to monitor the effect on hemostasis. This study aims to assess how hemostatic management… read more here.
Keywords: act 120; factor inhibitors; xaban patients; direct factor ... See more keywords
Applying index of circulating anticoagulant to mixing tests with lupus anticoagulant screen and confirm reagents can distinguish with high specificity between lupus anticoagulants and direct factor Xa inhibitors
Sign Up to like & getrecommendations! Published in 2021 at "International Journal of Laboratory Hematology"
DOI: 10.1111/ijlh.13571
Abstract: Lupus anticoagulants (LA) are detected by prolongation of clotting times for dilute Russell's viper venom time (dRVVT) and activated partial thromboplastin time (APTT) screening tests. Direct oral anticoagulants (DOACs) can interfere with both screening and… read more here.
Keywords: factor inhibitors; lupus anticoagulants; mixing tests; direct factor ... See more keywords